Viatris Forms Eye Care Unit from Acquisitions
Viatris, formed in November 2020 from the merger of Mylan with Pfizer’s Upjohn division, has established an eye care division following the closure of two acquisitions on Jan. 3.
Mylan
Upjohn/Mylan Merger Closes to Form Viatris
Pfizer has completed the spin-off of its Upjohn Business and combined it with Mylan to form Viatris, which began trading on Nov. 17. On closure of the deal, Pfizer stockholders owned about 57% of the outstanding shares of Viatris common stock and Mylan shareholders owned roughly 43%.
Mylan Buys Aspen’s European Thrombosis Assets
Mylan has agreed to buy the related intellectual property and commercialization rights of Aspen Pharmacare’s European thrombosis business for €641.9 million. The company will use proceeds from the sale to pay down debt.
Mylan Invests Again in Mapi’s MS Therapy
US generics specialist Mylan is investing an additional $20 million in Mapi Pharma to support the latter’s ongoing Phase 3 clinical study and eventual commercialization of Glatiramer Acetate (GA) Depot for treating patients with relapsing-remitting multiple sclerosis (RRMS) in the US.
